Skip to main content

Table 1 Summary of included cohort studies and characteristics

From: Bisphosphonates and risk of atrial fibrillation: a meta-analysis

Study, year, country Subjects Mean age
Mean follow-up (years) Type of bisphosphonate AF definition Total AF events (n) Variables matched and/or controlled Quality assessment score§
Bunch and colleagues [15], 2009, USA 9,623 (98 BIS users and 9,525 non-users) in angiographic research database 60 4.1 Alendronate
Zoledronic acid
Hospital discharge ICD-9 codes and EKG data 974 Age, HTN, hyperlipidemia, DM, HF, CAD, etc 4/2/3
  37,485 (7,489 BIS users and 29,996 non-users) in a commercial health care system database 51 4.6    1012   
Abrahamsen and colleagues [14], 2009, Denmark 43,033 patients (14,302 BIS users and 28,731 non-users) with fractures in the National Hospital Discharge register 74 2.7 Alendronate
Prescription for a cardiac glycoside +/- ICD-10 codes 797 * Age, gender, fracture sites, medications use for DM, HTN, hypercholesterolemia, and thrombosis, and Charlson index 4/2/3
Huang and colleagues [17], 2009, Taiwan 27,257 women (21,037 BIS users and 6,220 raloxifene users) with osteoporosis in the National Health Insurance database 74 0.6 Alendronate Inpatient or outpatient ICD-9 codes 821 DM, CAD, COPD, history of AF, HTN, and total defined daily dose of drugs 3/2/2
  1. * only in BIS users, § Methodologic quality assessment score based on Newcastle-Ottawa Scale [23]; selection (0 to 4), comparability (0 to 2), and outcome score (0 to 3) points with a higher score representing a better quality.
  2. AF, atrial fibrillation; BIS, bisphosphonates; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EKG, electrocardiogram; HF, heart failure; HTN, hypertension; ICD, International Classification of Diseases.